Nowhere has there been more controversy in recent years than in the use of high dose chemotherapy (HDC) with autologous hematopoietic stem cell transplantation for breast cancer, both in the adjuvant setting and for advanced disease. Authors review and comment on the data from the studies so far reported and try to indicate what will be next in this field. They also discuss what may be the attitude to take in our everyday clinical practice, taking into account the availability of new chemotherapeutic agents and targeted therapies.
High dose chemotherapy and hematopoietic progenitor cell transplantation for breast cancer / P. Pedrazzoli, E. Tarenzi, C. Tullio, G. Colosini, S. Siena. - In: JOURNAL OF CHEMOTHERAPY. - ISSN 1120-009X. - 16:Suppl. 4(2004 Nov), pp. 108-111. (Intervento presentato al 1. convegno ISC International Conference on Cancer Therapeutics : Molecular Targets, Pharmacology and Clinical Applications : Februar, 19-21 tenutosi a Florence nel 2004) [10.1179/joc.2004.16.Supplement-1.108].
High dose chemotherapy and hematopoietic progenitor cell transplantation for breast cancer
S. SienaUltimo
2004
Abstract
Nowhere has there been more controversy in recent years than in the use of high dose chemotherapy (HDC) with autologous hematopoietic stem cell transplantation for breast cancer, both in the adjuvant setting and for advanced disease. Authors review and comment on the data from the studies so far reported and try to indicate what will be next in this field. They also discuss what may be the attitude to take in our everyday clinical practice, taking into account the availability of new chemotherapeutic agents and targeted therapies.
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
